ApoB vs LDL cholesterol: which number measures your actual risk
LDL cholesterol measures mass; apoB counts particles. Why the two disagree, when a normal LDL-C reassures you for the wrong reason, and what apoB values European guidelines name.
A standard lipid panel hands you LDL cholesterol. It is the most-cited number in cardiovascular prevention and the one most decisions are made on. But LDL-C does not measure what most people assume it measures — and there is a marker that gets at the underlying quantity far more directly.
What apoB actually measures
Cholesterol does not travel loose in the bloodstream. It moves packaged inside lipoprotein particles, and it can only enter the arterial wall while inside one. The structural fact that makes this measurable is that every atherogenic particle — LDL, VLDL, IDL, lipoprotein(a) — carries exactly one apolipoprotein B molecule. 1
So the apoB concentration in your blood is the number of particles capable of entering the arterial wall. Not a proxy for it. The count.
LDL-C, by contrast, tells you how much cholesterol all your LDL particles are carrying between them. It is the weight of the cargo, not the number of vehicles.
Why the two numbers disagree
If every particle carried the same cholesterol load, both numbers would say the same thing and this article would not exist. But cholesterol content per particle varies between people and over time, and that variability is the physiological reason apoB works better as a risk marker than either LDL-C or non-HDL-C. 2
Here is what that looks like in practice. Someone whose particles are small and cholesterol-poor needs more of them to carry the same total mass. Their LDL-C comes back unremarkable while their particle count — and therefore the exposure their artery wall is under — is high. LDL-C reassured them. ApoB would not have.
This mismatch is called discordance, and it is not a fringe case. It shows up most in people with elevated triglycerides, diabetes, obesity or metabolic syndrome — which is precisely the population where European guidelines explicitly recommend measuring apoB. 3
What counts as a good number
One mental model needs correcting first: the target is not a universal number. It is a function of your risk. The 2019 European guidelines name apoB as a secondary goal across three bands by risk category. 3
Secondary treatment goals. A lower risk category means a looser target — the goal is a function of your risk, not a universal number.
Making it useful
A single apoB value tells you relatively little. What carries information is the trend across draws and what changed between them — diet, weight, a new medication, a different training block. That context is usually what gets lost: results stay in a lab PDF, and each year only the newest value gets compared against a reference range.
A second practical note concerns units. Czech labs report apoB in g/L, while English-language literature and European guidelines use mg/dL. The conversion is straightforward — 0.65 g/L is 65 mg/dL — but it is an easy way to misread your own result against a number you saw in an article.
Frequently asked
›Does apoB replace a standard lipid panel?
No — it complements it. Guidelines still treat LDL-C as the primary value for screening and monitoring, and name apoB as an alternative and as a secondary goal that is more accurate wherever the two disagree. 3
›Is apoB an expensive test?
It is a routine immunoassay run from the same draw as your lipid panel, so nothing extra needs collecting. Price and coverage vary by lab and indication — worth asking before you go.
›Do I need to fast?
Generally not, which is one of its practical advantages over calculated LDL-C, which is more sensitive to fasting state. Confirm with the lab doing your draw.
References
- [1]Apolipoprotein B Particles and Cardiovascular Disease: A Narrative ReviewJAMA Cardiology 2019;4(12):1287-1295 · 2019 · systematic-reviewArgues apoB measures the number of atherogenic particles, since each atherogenic lipoprotein particle carries exactly one apoB molecule, and that cholesterol enters the arterial wall inside those particles — so particle count is the more direct measure of atherogenic exposure than the cholesterol mass they carry.
- [2]Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular RiskJournal of the American Heart Association 2022 · 2022 · systematic-reviewSets out the physiological reasons apoB outperforms LDL-C and non-HDL-C as a risk marker, centred on the variable cholesterol content of individual particles.
- [3]2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal (ESC/EAS Task Force) · 2020 · guidelineDefines apoB secondary goals by risk category (<65 mg/dL very high, <80 mg/dL high, <100 mg/dL moderate) and recommends apoB measurement for risk assessment, particularly with high triglycerides, diabetes, obesity, metabolic syndrome or very low LDL-C.